Reported Earnings • Aug 11
Second quarter 2026 earnings released: EPS: US$0.097 (vs US$0.19 in 2Q 2025) Second quarter 2026 results: EPS: US$0.097 (down from US$0.19 in 2Q 2025). Revenue: US$622.7m (up 25% from 2Q 2025). Net income: US$7.53m (down 48% from 2Q 2025). Profit margin: 1.2% (down from 2.9% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. New Risk • Aug 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Significant insider selling over the past 3 months (€2.6m sold). Announcement • Jul 23
RadNet, Inc. to Report Q2, 2026 Results on Aug 10, 2026 RadNet, Inc. announced that they will report Q2, 2026 results on Aug 10, 2026 Announcement • May 01
RadNet, Inc. (NasdaqGM:RDNT) acquired an unknown majority stake in Intermountain Medical Imaging, Llc. RadNet, Inc. (NasdaqGM:RDNT) acquired an unknown majority stake in Intermountain Medical Imaging, Llc on April 30, 2026. The acquisition forms a new joint venture with Saint Alphonsus Health System, which is part of Trinity Health. RadNet will assume management of the five locations. The new joint venture is projected to generate approximately $30 million in annual revenue for RadNet.
RadNet, Inc. (NasdaqGM:RDNT) completed the acquisition of an unknown majority stake in Intermountain Medical Imaging, Llc on April 30, 2026. Announcement • Apr 21
RadNet, Inc., Annual General Meeting, Jun 02, 2026 RadNet, Inc., Annual General Meeting, Jun 02, 2026. Location: 1510 cotner avenue, california 90025, los angeles United States Announcement • Feb 04
RadNet, Inc. (NasdaqGM:RDNT) acquired Outpatient Imaging Assets of Northwest Radiology Network, P.C. RadNet, Inc. (NasdaqGM:RDNT) acquired Outpatient Imaging Assets of Northwest Radiology Network, P.C. on February 3, 2026.
RadNet, Inc. (NasdaqGM:RDNT) completed the acquisition of Outpatient Imaging Assets of Northwest Radiology Network, P.C. on February 3, 2026. Announcement • Nov 18
RadNet, Inc. and DeepHealth, Inc. Announces Results from the Real-World Analysis of AI-Driven Breast Cancer Screening Ever Conducted in the United States RadNet, Inc. and its wholly owned subsidiary, DeepHealth announced results from the real-world analysis of AI-driven breast cancer screening ever conducted in the United States. Published in Nature Health, the findings support the clinical effectiveness and benefit of DeepHealth's AI technology to deliver equitable results across several racial, ethnic and breast density patient groups. The AI-Supported Safeguard Review Evaluation (ASSURE) study examined the AI-powered workflow that is at the heart of RadNet's Enhanced Breast Cancer Detection™? (EBCD™?) program. This study included mammograms from over 5579,000 women across 109 community-based imaging sites in California, Delaware, Maryland and New York. The research compared 3D mammography screening to a novel AI-driven protocol that combines DeepHealth's FDA-cleared computer-aided detection and diagnosis (CADe/x) software with an AI-supported Safeguard Review workflow, which can trigger a second breast imaging expert review of high-suspicion cases--a workflow that RadNet now offers as EBCD™?. Together, they deliver these benefits across patient populations, including the more than 150,000 Black women enrolled. Black women face 40% higher breast cancer mortality in the United States. Furthermore, the ASSURE study showed that the workflow underlying RadNet's EBCD™? program delivered a 22.7% boost in cancer detection rate compared to 3D mammography screening for women with dense breasts, who experience both increased cancer risk and diagnostic challenges. Announcement • Nov 10
RadNet, Inc. Updates Earnings Guidance for the Full Year 2025 RadNet, Inc. updated earnings guidance for the full year 2025. For the year, the company now expects Imaging center segment total net revenue of $1,900 - $1,930 million against previously revised guidance after second quarter of $1,850 - $1,900 million. For Digital Health segment, the company expects total net revenue of (inclusive of intersegment revenue) of $85 million - $95 million against previous guidance of $80 million - $90 million. Recent Insider Transactions • Aug 18
Executive VP recently sold €991k worth of stock On the 13th of August, David Katz sold around 17k shares on-market at roughly €58.31 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €5.0m. Insiders have been net sellers, collectively disposing of €15m more than they bought in the last 12 months. Announcement • Aug 12
RadNet, Inc. Updates Earnings Guidance for the Full Year 2025 RadNet, Inc. updated earnings guidance for the full year 2025. For the year, the company now expects Imaging center segment total net revenue of $1,850 - $1,900 million against previously revised guidance after First Quarter of $1,835 million - $1,885 million. For Digital Health segment, the company expects total net revenue of (inclusive of intersegment revenue) of $80 million - $90 million against previous guidance of $80 million - $90 million. Announcement • Apr 29
RadNet, Inc., Annual General Meeting, Jun 10, 2025 RadNet, Inc., Annual General Meeting, Jun 10, 2025. Location: at our principalexecutive office, at 1510 cotner avenue, ca 90025., los angeles United States Announcement • Apr 16
RadNet, Inc. (NasdaqGM:RDNT) entered into an Agreement and Plan of Merger to acquire iCAD, Inc. (NasdaqCM:ICAD) for approximately $100 million. RadNet, Inc. (NasdaqGM:RDNT) entered into an Agreement and Plan of Merger to acquire iCAD, Inc. (NasdaqCM:ICAD) for approximately $100 million on April 15, 2025. Under the terms of the merger agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger. Sell side termination fee is $1 million. The transaction is subject to approval by iCAD stockholders, the effectiveness of a registration statement on Form S-4 of RadNet and other customary closing conditions, and was unanimously approved by each company’s board of directors. The transaction is expected to close in the second or third quarter of 2025. Andrew Moore and David Martinez of Perkins Coie LLP and Reed Smith LLP are serving as legal counsel to RadNet. Piper Sandler & Co. is serving as financial advisor and fairness opinion provider to iCAD and Jeffrey A. Baume and lIlan Katz of Dentons US LLP is serving as iCAD’s legal counsel. Announcement • Feb 28
RadNet, Inc. Provides Financial Guidance for the Fiscal Year 2025 RadNet, Inc. provided financial guidance for the fiscal year 2025. For the year, company expects Total Net Revenue for imaging center segment of $1,825 million to $1,875 million and Total Net Revenue for Digital Health Segment of $80 million to $90 million. Reported Earnings • Nov 11
Third quarter 2024 earnings released: EPS: US$0.044 (vs US$0.26 in 3Q 2023) Third quarter 2024 results: EPS: US$0.044 (down from US$0.26 in 3Q 2023). Revenue: US$461.1m (up 15% from 3Q 2023). Net income: US$3.21m (down 82% from 3Q 2023). Profit margin: 0.7% (down from 4.4% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance. Announcement • Nov 11
RadNet, Inc. Revises Earnings Guidance for the Year 2024 RadNet, Inc. revised earnings guidance for the year 2024. For the year, company expects total revenue to be in range of $1,710 million to $1,760 million compared to previous guidance of $1,685 million to $1,735 million. Announcement • Sep 13
RadNet, Inc. Appoints Cornelis “Kees” Wesdorp as President and Chief Executive Officer of its Digital Health Segment, Effective October 1, 2024 On September 11, 2024 RadNet, Inc. (“RadNet”) appointed Cornelis “Kees” Wesdorp, age 47, to serve as President and Chief Executive Officer of its Digital Health segment (“Digital Health”), which includes RadNet’s eRad and Artificial Intelligence businesses, effective October 1, 2024. Prior to joining RadNet, Mr. Wesdorp served as a Managing Director of the private equity firm Hellman & Friedman in London, where he co-led the EU Operations group since February 2023. From 2017 to 2022 Mr. Wesdorp was an executive with Phillips Group in Amsterdam, starting as an executive vice president overseeing the Diagnostic Imaging businesses before being promoted in 2020 to Phillip’s executive committee with responsibility for overseeing the multi-billion euro Precision Diagnosis Division, focused on diagnostic imaging solutions for health systems including imaging systems, informatics and artificial intelligence. From 2011 to 2016, Mr. Wesdorp was an executive vice president with the private equity firm Bain Capital in London, performing various operating partner roles for portfolio companies. From 2006 to 2011, he served in various management roles with NXP Semiconductor, a semiconductor manufacturing and design company based in Eindhoven, Netherlands. Mr. Wesdorp began his career at McKinsey & Company in Amsterdam. Mr. Wesdorp earned a Masters Degree in Physics from the University of Amsterdam and a PhD in Experimental Atomic Physics from Vrije University in Amsterdam. On September 11, 2024, Mr. Cornelis “Kees” Wesdorp entered into an employment agreement (the “Employment Agreement”) with Aidence B.V., a wholly owned subsidiary of RadNet, which provides that he will serve as a director of Aidence B.V. and as President and Chief Executive Officer of RadNet Digital Health. Mr. Wesdorp will be based in the Netherlands. The employment term will start October 1, 2024, and will continue until terminated by either RadNet or Mr. Wesdorp. Recent Insider Transactions • Aug 23
Insider recently sold €846k worth of stock On the 21st of August, Michael Murdock sold around 15k shares on-market at roughly €56.40 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €3.9m. Insiders have been net sellers, collectively disposing of €17m more than they bought in the last 12 months. Reported Earnings • Aug 08
Second quarter 2024 earnings released: US$0.041 loss per share (vs US$0.14 profit in 2Q 2023) Second quarter 2024 results: US$0.041 loss per share (down from US$0.14 profit in 2Q 2023). Revenue: US$459.7m (up 14% from 2Q 2023). Net loss: US$2.98m (down 136% from profit in 2Q 2023). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. New Risk • Aug 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Significant insider selling over the past 3 months (€16m sold). Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Executive VP, Chief Science Officer & Director Greg Sorensen was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Jun 13
Executive VP recently sold €930k worth of stock On the 7th of June, David Katz sold around 16k shares on-market at roughly €56.68 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.6m more than they bought in the last 12 months. Reported Earnings • May 09
First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.36 loss in 1Q 2023) First quarter 2024 results: US$0.04 loss per share (improved from US$0.36 loss in 1Q 2023). Revenue: US$431.7m (up 11% from 1Q 2023). Net loss: US$2.78m (loss narrowed 87% from 1Q 2023). Revenue is forecast to grow 7.7% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings. Announcement • Apr 28
RadNet, Inc., Annual General Meeting, Jun 12, 2024 RadNet, Inc., Annual General Meeting, Jun 12, 2024, at 10:00 Pacific Standard Time. Location: 1510 Cotner Ave. Los Angeles California United States Agenda: To consider and elect the Directors; to consider the The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024; to consider and approve the compensation of the Company's Named Executive Officers; and to consider other business matters. Buy Or Sell Opportunity • Mar 06
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 31% to €43.00. The fair value is estimated to be €35.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 16% in 2 years. Earnings are forecast to grow by 1,612% in the next 2 years. Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: US$0.048 (vs US$0.19 in FY 2022) Full year 2023 results: EPS: US$0.048 (down from US$0.19 in FY 2022). Revenue: US$1.62b (up 13% from FY 2022). Net income: US$3.04m (down 71% from FY 2022). Profit margin: 0.2% (down from 0.7% in FY 2022). Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Recent Insider Transactions • Dec 08
Insider recently sold €328k worth of stock On the 5th of December, Michael Murdock sold around 10k shares on-market at roughly €32.45 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.6m more than they bought in the last 12 months. Announcement • Dec 07
RadNet, Inc. Launches a Pilot Inside Walmart of its New MammogramNow™ Offering RadNet, Inc. announced MammogramNow, an innovative screening mammography service set to debut at the Walmart Supercenter in Milford, Delaware, on December 8th. This pioneering initiative aims to enhance breast health awareness and accessibility, including the integration of cutting-edge DeepHealth® (deephealth.com) technology, into the Walmart Supercenter environment, providing women with convenient access to crucial breast cancer screening services. By placing the MammogramNow program within the Walmart Supercenter, RadNet and Walmart seek to make breast health screenings more accessible, encouraging proactive, community-based healthcare. As part of the pilot, RadNet will actively promote breast health education and awareness initiatives, providing the Milford community with essential information about breast health and the critical nature of regular screenings. Announcement • Nov 29
RadNet, Inc. Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio RadNet, Inc. announced the launch of DeepHealth, a health informatics portfolio designed to dramatically drive efficiency and transform radiology's role in healthcare. RadNet is embracing an increasing responsibility in healthcare screening, surveillance and follow-up care programs. The expanded role of radiology within healthcare, combined with ongoing operational and economic pressures impacting all healthcare specialties, require a transformative shift in radiology informatics to drive efficiency and scalability. DeepHealth aims to address this paradigm shift by introducing a pioneering cloud-native operating system (OS), powered by clinical AI, that improves disease detection and that leverages operational generative AI, to efficiently orchestrate patient engagement and care delivery. The newly launched portfolio builds on the strengths of RadNet's existing digital health businesses and products, including eRAD Radiology Information and Image Management Systems, Aidence lung AI, Quantib prostate AI and DeepHealth breast AI. This synergy, combined with RadNet's extensive data, clinical and operational expertise, position DeepHealth portfolio to deliver scalable solutions for patients and professionals in the care continuum. At the heart of the DeepHealth portfolio is DeepHealth OS, a cloud-native workflow engine intended to integrate data across an enterprise with API-based modules and to offer personalized workflow applications for a multitude of roles. DeepHealth OS embeds AI-powered clinical insights and automation for each clinical professional--radiologists, technologists and referring physicians. Additionally, DeepHealth intends to provide operational professionals, such as practice managers, schedulers, patient liaisons and revenue cycle teams, their own AI-enabled applications to manage care delivery more efficiently and effectively. These personalized applications on a common workflow engine can simplify the care delivery experience, orchestrate collaboration and help to elevate every professional's performance. elements of the DeepHealth portfolio are already being used by RadNet and more than 300 external customers, who together are delivering more than 15 million exams annually. DeepHealth AI solutions have powered more than two million diagnoses in large screening programs in both the United States and Europe, driving potentially improved clinical outcomes. Reported Earnings • Nov 10
Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.012 in 3Q 2022) Third quarter 2023 results: EPS: US$0.26 (up from US$0.012 in 3Q 2022). Revenue: US$402.0m (up 15% from 3Q 2022). Net income: US$17.5m (up US$16.9m from 3Q 2022). Profit margin: 4.4% (up from 0.2% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 1.4% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. New Risk • Aug 10
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.4x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Significant insider selling over the past 3 months (€1.4m sold). Announcement • Aug 10
RadNet, Inc. Appoints Dr. Gregory Sorensen as Executive Vice President and Chief Science Officer On August 4, 2023, RadNet, Inc. appointed Dr. Gregory Sorensen, M.D. to the Board of Directors (the Board") and to serve as the Company's Executive Vice President and Chief Science Officer, with such appointment effective August 8, 2023. From 2017 to the present, Dr. Sorensen, age 61, has served as the Chief Executive Officer of DeepHealth, Inc. (DeepHealth"), a subsidiary of the Company that is focused on using artificial intelligence and deep learning methods to advance medical care with a special emphasis on breast cancer imaging. The Company acquired DeepHealth in June 2020. Dr. Sorensen served as the President and Chief Executive Officer of Siemens Healthcare North America from 2011 to 2015. Prior to that, he served as a Professor at Harvard Medical School and as a neuroradiologist at Massachusetts General Hospital, where he worked from 1990 to 2011. Dr. Sorensen currently serves as: the Executive Chairman of the board of directors of IMRIS, Deerfield Imaging, Inc., which is focused on the integration of imaging technologies in a neurosurgical setting; a Board member for RealmIDX, Inc., an integrated diagnostics company wholly owned by KonicaMinolta; and a member of the Supervisory Board for Fresenius Medical Care AG & Co KGaA, a provider of products and services for people with chronic kidney failure. Dr. Sorensen served as a Supervisory Board Member at Siemens Healthineers from 2018 to 2023. Dr. Sorensen holds a B.S. in biology from the California Institute of Technology, an M.S. in computer science from Brigham Young University, and an M.D. degree from Harvard Medical School. Reported Earnings • Aug 09
Second quarter 2023 earnings released: EPS: US$0.14 (vs US$0.14 in 2Q 2022) Second quarter 2023 results: EPS: US$0.14. Revenue: US$403.7m (up 14% from 2Q 2022). Net income: US$8.37m (up 5.9% from 2Q 2022). Profit margin: 2.1% (in line with 2Q 2022). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Announcement • Aug 09
Radnet, Inc. Revises Earnings Guidance for the Year 2023 RadNet, Inc. revised earnings guidance for the year 2023. For the year, company expects total revenue to be in range of $1,575 Million - $1,610 Million against previous guidance of $1,550 Million - $1,600 million. Announcement • Aug 02
RadNet, Inc. Announces Appointment of Executives RadNet, Inc. announced the addition of two executives to lead advancements in the company’s technology solutions, including its current portfolio of radiology informatics (eRAD Radiology Information and Image Management Systems and related solutions) and clinical and generative Artificial Intelligence (AI). Sham Sokka, PhD., has been named Chief Operating and Technology Officer of Digital Health at RadNet. Sanjog Misra has joined the company as Chief Commercial Officer of Digital Health. Dr. Sokka contributes significant executive-level experience in business, marketing, and innovation from his 20-year tenure at Philips. Dr. Sokka most recently served as Senior Vice-President of Innovation and Marketing for Philips Precision Diagnosis business cluster. Prior to that role, he has led informatics and services businesses: the Ventures and Radiology Solutions businesses of that same cluster. Dr. Sokka obtained his PhD from the MIT-Harvard division of Health, Sciences, and Technology and earlier in his career also led clinical development in oncology and imaging systems, helping to introduce novel MR-guided therapy systems for oncology. Mr. Misra also joins RadNet from Philips, where his last position was Vice President of Enterprise Solutions, Commercial Leader of Diagnostic Imaging Chains and Head of Philips Capital, North America. Over the last 14 years at Philips, Mr. Misra has worked in various commercial and finance leadership roles handling Solution Sales and Corporate Finance across geographies that include India, the Asia Pacific. Announcement • Jun 15
RadNet, Inc. has completed a Follow-on Equity Offering in the amount of $225.35625 million. RadNet, Inc. has completed a Follow-on Equity Offering in the amount of $225.35625 million.
Security Name: Common stock
Security Type: Common Stock
Securities Offered: 7,575,000
Price\Range: $29.75 Recent Insider Transactions • Jun 12
President & COO of Western Operations recently sold €1.3m worth of stock On the 8th of June, Norman Hames sold around 45k shares on-market at roughly €28.82 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.2m more than they bought in the last 12 months. Announcement • Jun 09
RadNet, Inc. Announces Ruth V. Wilson Did Not to Stand for Re-Election to the Board of Directors RadNet, Inc. announced that Ruth V. Wilson did not to stand for re-election to the Board of Directors of at the Company’s Annual Meeting of Stockholders held on June 7, 2023 (the “ Annual Meeting”). She has resigned her position as a member of the Board of Directors of the Company and any and all committees of the Board of Directors of the Company on which she serves, effective at the conclusion of the Annual Meeting. Her resignation is not related to any disagreement with the Company on any matter relating to its operations, policies or practices. Recent Insider Transactions • May 26
Board Member recently sold €128k worth of stock On the 23rd of May, Christine Gordon sold around 5k shares on-market at roughly €26.31 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €418k. Insiders have been net sellers, collectively disposing of €1.2m more than they bought in the last 12 months. Announcement • May 26
RadNet, Inc., Annual General Meeting, Jun 07, 2023 RadNet, Inc., Annual General Meeting, Jun 07, 2023, at 10:00 Pacific Standard Time. Agenda: To consider approval of an amendment and restatement of the Equity Incentive Plan; and to consider other matters. Announcement • May 12
RadNet, Inc. Revises Earnings Guidance for the Year 2023 RadNet, Inc. revised earnings guidance for the year 2023. For the year, the company expects revenue of $1,550 million to $1,600 million compared to previous guidance of $1,525 million to $1,575 million. Reported Earnings • May 12
First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.054 profit in 1Q 2022) First quarter 2023 results: US$0.36 loss per share (down from US$0.054 profit in 1Q 2022). Revenue: US$390.6m (up 14% from 1Q 2022). Net loss: US$21.0m (down US$24.0m from profit in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 27% per year. Recent Insider Transactions • Mar 19
President & COO of Eastern Operations recently sold €217k worth of stock On the 16th of March, Stephen Forthuber sold around 10k shares on-market at roughly €21.68 per share. This transaction amounted to 1.9% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €418k. Insiders have been net sellers, collectively disposing of €1.0m more than they bought in the last 12 months. Recent Insider Transactions • Mar 08
Insider recently sold €418k worth of stock On the 3rd of March, Ruth Villiger-Wilson sold around 18k shares on-market at roughly €23.52 per share. This transaction amounted to 64% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €814k more than they bought in the last 12 months. Reported Earnings • Mar 03
Full year 2022 earnings released: EPS: US$0.19 (vs US$0.47 in FY 2021) Full year 2022 results: EPS: US$0.19 (down from US$0.47 in FY 2021). Revenue: US$1.43b (up 8.0% from FY 2021). Net income: US$10.7m (down 57% from FY 2021). Profit margin: 0.7% (down from 1.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Feb 07
Radiology Imaging Associates Launches the Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered by Artificial Intelligence Radiology Imaging Associates, a division of RadNet, Inc. announced that it has started implementation of its new Enhanced Breast Cancer Detection service, which works in concert with a patient's annual breast screening regimen. For an additional fee, patients can receive an advanced screening mammography service including the application of Saige-Dx™, an FDA-cleared artificial intelligence (AI) technology powered by DeepHealth; an additional AI-driven review applied to certain suspicious exams and findings; an in-depth personalized lifetime risk assessment for breast cancer; and a dedicated 1-800 support line for questions about certain aspects of the patient's reports. EBCD presents a significantly improved level of accuracy in breast cancer detection, empowering women to take greater control of their health. In the past, many breast screening mammography patients have described a desire for more information about the reports and follow-ups they receive after their annual mammogram, including their lifetime risk of developing breast cancer. While a breast density score, currently required in 38 states, is one factor in a patient's lifetime risk for breast cancer, multiple factors can increase risk. The EBCD service offers a much-needed solution that addresses questions about breast cancer risk by providing a personalized report and a specialist to call when patients have questions about their lifetime risk of breast cancer. Depending on the patient's risk level, their referring physician might recommend a customized screening protocol. The EBCD service was created for women who want more accurate and informative mammograms. EBCD is the first comprehensive solution of its kind. Recent Insider Transactions • Dec 21
President & COO of Western Operations recently sold €92k worth of stock On the 19th of December, Norman Hames sold around 5k shares on-market at roughly €18.33 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €396k more than they bought in the last 12 months. Reported Earnings • Nov 11
Third quarter 2022 earnings released: EPS: US$0.012 (vs US$0.31 in 3Q 2021) Third quarter 2022 results: EPS: US$0.012 (down from US$0.31 in 3Q 2021). Revenue: US$350.0m (up 5.2% from 3Q 2021). Net income: US$668.0k (down 96% from 3Q 2021). Profit margin: 0.2% (down from 4.9% in 3Q 2021). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Nov 10
RadNet, Inc. Provides Earnings Guidance for the Full Year of 2022 RadNet, Inc. provided earnings guidance for the full year of 2022. Revenue – Imaging Ctr Operations is expected $1,360 million to $1,410 million. Announcement • Nov 02
RadNet, Inc. (NasdaqGM:RDNT) acquired 75% stake in Heart & Lung Imaging Limited. RadNet, Inc. (NasdaqGM:RDNT) acquired 75% stake in Heart & Lung Imaging Limited on November 01, 2022.
RadNet, Inc. (NasdaqGM:RDNT) completed the acquisition of 75% stake in Heart & Lung Imaging Limited on November 01, 2022. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 20% share price gain to €21.40, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 11x in the Healthcare industry in Germany. Total returns to shareholders of 67% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.64 per share. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improved over the past week After last week's 16% share price gain to €22.60, the stock trades at a forward P/E ratio of 61x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.31 per share. Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: US$0.14 (vs US$0.055 in 2Q 2021) Second quarter 2022 results: EPS: US$0.14 (up from US$0.055 in 2Q 2021). Revenue: US$354.4m (up 6.1% from 2Q 2021). Net income: US$7.91m (up 175% from 2Q 2021). Profit margin: 2.2% (up from 0.9% in 2Q 2021). Over the next year, revenue is forecast to grow 4.7%, compared to a 2.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 10
RadNet, Inc. Updates Earnings Guidance for 2022 RadNet, Inc. updated earnings guidance for 2022. For the period, the company now expects total revenue in the range of $1,360 million to $1,410 million as compared to $1,350 million to $1,400 million as previously guided. Recent Insider Transactions • Jun 03
President & COO of Western Operations recently sold €193k worth of stock On the 1st of June, Norman Hames sold around 10k shares on-market at roughly €19.27 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €594k more than they bought in the last 12 months. Announcement • May 18
RadNet, Inc. Announces That It Has Received FDA Clearances for Its DeepHeatlh Saige-DX™ Mammography and Quantib® Prostate 2.0 MRI Artificial Intelligence ("Ai") Algorithms RadNet, Inc. announced that it has received FDA clearances for its DeepHeatlh Saige-DX™ mammography and Quantib® Prostate 2.0 MRI artificial intelligence ("AI") algorithms. Saige-Dx, a more advanced successor to FDA approved Saige-Q worklist triage software, is a cancer detection tool that enables radiologists to more effectively detect the presence or absence of breast cancer with the use of artificial intelligence. DeepHealth's powerful new AI technology automatically identifies suspicious lesions in mammograms and assigns a suspicion level to each finding and to the entire case. It helps detect and diagnose breast cancer earlier while reducing unnecessary recalls.Quantib® Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station. The solution comes with a suite of tools to improve reporting quality and speed, including AI-based segmentations and volumetry, PSA density calculation, precise registration and movement correction, one-click segmentation of lesion candidates, PI-RADS scoring support, and standardized reporting to facilitate easy and comprehensive communication of results. FDA 510k special clearance has been given for a major upgrade to the solution (from release 1.3) that now includes fully automatic prostate zone segmentation (in addition to prostate gland segmentation) and automated initiation of localization of lesions on the PI-RADS sector map. Reported Earnings • May 11
First quarter 2022 earnings released: EPS: US$0.054 (vs US$0.18 in 1Q 2021) First quarter 2022 results: EPS: US$0.054 (down from US$0.18 in 1Q 2021). Revenue: US$341.8m (up 6.3% from 1Q 2021). Net income: US$3.01m (down 68% from 1Q 2021). Profit margin: 0.9% (down from 2.9% in 1Q 2021). Over the next year, revenue is forecast to grow 4.3%, compared to a 4.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Announcement • May 10
RadNet, Inc. Revises Earnings Guidance for the Fiscal Year 2022 RadNet, Inc. revised earnings guidance for the fiscal year 2022. For the year, company expects total net revenue of $1,360 million - $1,410 million against previous guidance of $1,350 million to $1,400 million. Announcement • May 02
RadNet, Inc., Annual General Meeting, Jun 08, 2022 RadNet, Inc., Annual General Meeting, Jun 08, 2022, at 10:00 Pacific Standard Time. Location: principal executive office at 1510 Cotner Avenue, Los Angels California United States Agenda: To consider election of seven nominees as directors to hold office until the 2023 Annual Meeting of Stockholders, or until their successors are duly elected and qualified; to consider the ratification of the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2022; to consider a non-binding advisory vote to approve executive compensation; and to consider Other business that may properly come before the Annual Meeting. Announcement • Mar 04
RadNet, Inc. Provides Earnings Guidance for the Fiscal Year 2022 RadNet, Inc. provided earnings guidance for the fiscal year 2022. For the year, company expects total net revenue of $1,350 million to $1,400 million. Reported Earnings • Mar 03
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: US$0.47 (up from US$0.29 loss in FY 2020). Revenue: US$1.32b (up 21% from FY 2020). Net income: US$24.7m (up US$39.6m from FY 2020). Profit margin: 1.9% (up from net loss in FY 2020). Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 5.1%, compared to a 4.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Reported Earnings • Nov 10
Third quarter 2021 earnings released: EPS US$0.31 (vs US$0.12 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$332.7m (up 14% from 3Q 2020). Net income: US$16.2m (up 164% from 3Q 2020). Profit margin: 4.9% (up from 2.1% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. Recent Insider Transactions • Sep 04
Senior VP of Human Resources & Director recently sold €86k worth of stock On the 2nd of September, Ruth Wilson sold around 3k shares on-market at roughly €26.53 per share. In the last 3 months, they made an even bigger sale worth €388k. Insiders have been net sellers, collectively disposing of €3.8m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$27.00, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 15x in the Healthcare industry in Germany. Total returns to shareholders of 119% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.47 per share. Recent Insider Transactions • Aug 14
Lead Independent Director recently bought €129k worth of stock On the 11th of August, David Swartz bought around 5k shares on-market at roughly €28.52 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €3.7m more in shares than they bought in the last 12 months. Reported Earnings • Aug 10
Second quarter 2021 earnings released: EPS US$0.055 (vs US$0.21 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$334.0m (up 55% from 2Q 2020). Net income: US$2.87m (up US$13.5m from 2Q 2020). Profit margin: 0.9% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jun 17
Senior VP of Human Resources & Director recently sold €388k worth of stock On the 10th of June, Ruth Wilson sold around 15k shares on-market at roughly €25.90 per share. In the last 3 months, there was an even bigger sale from another insider worth €404k. Insiders have been net sellers, collectively disposing of €4.1m more than they bought in the last 12 months. Executive Departure • Jun 15
Independent Director Marvin Cadwell has left the company On the 10th of June, Marvin Cadwell's tenure as Independent Director ended after 14.4 years in the role. As of March 2021, Marvin still personally held 285.48k shares (€5.3m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 9.46 years. Executive Departure • Jun 15
VP, Medical Director & Director John Crues has left the company On the 11th of June, John Crues' tenure as VP, Medical Director & Director ended. As of March 2021, John still personally held 435.26k shares (€8.1m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 9.46 years. Recent Insider Transactions • Jun 02
Insider recently sold €404k worth of stock On the 27th of May, Michael Murdock sold around 18k shares on-market at roughly €22.04 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.8m more than they bought in the last 12 months. Recent Insider Transactions • May 19
Independent Director recently bought €238k worth of stock On the 14th of May, Lawrence Levitt bought around 13k shares on-market at roughly €19.00 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €3.4m more in shares than they bought in the last 12 months. Reported Earnings • May 12
First quarter 2021 earnings released: EPS US$0.18 (vs US$0.33 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$321.6m (up 14% from 1Q 2020). Net income: US$9.46m (up US$25.8m from 1Q 2020). Profit margin: 2.9% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Announcement • May 11
RadNet, Inc. Revises Earnings Guidance for the Year 2021 RadNet, Inc. revised earnings guidance for the year 2021. For the year, the company expects total revenue to be in the range of $1,275 million - $1,325 million compared to previously provided guidance of $1,250 million - $1,300 million. Recent Insider Transactions • Mar 17
Independent Director recently sold €397k worth of stock On the 12th of March, Lawrence Levitt sold around 20k shares on-market at roughly €19.84 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.5m more than they bought in the last 12 months. Reported Earnings • Mar 10
Full year 2020 earnings released: US$0.29 loss per share (vs US$0.30 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$1.10b (down 4.9% from FY 2019). Net loss: US$14.8m (down 201% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 10
Revenue beats expectations Revenue exceeded analyst estimates by 0.7%. Over the next year, revenue is forecast to grow 12%, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Is New 90 Day High Low • Mar 10
New 90-day high: €19.90 The company is up 23% from its price of €16.20 on 10 December 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €33.83 per share. Announcement • Feb 11
RadNet and its Partner Dignity Health, Plaza Companies and Holualoa Companies Team Up to Redevelop Park Central RadNet, Inc. has signed a new lease for a 24,000-square-foot space in the Strauss Building at Park Central. The new space is part of an ongoing commitment by RadNet and its partner Dignity Health, which is part of CommonSpirit Health, to provide high-quality imaging services to targeted medical communities and patient populations. RadNet, through Dignity Health – Arizona Diagnostic Radiology, will provide a full-service imaging clinic including MRI, CT, Nuclear Imaging and Mammography at the Park Central location, meeting a key need for the local medical community. Plaza Companies and Tucson’s Holualoa Companies have teamed up to redevelop Park Central into a vibrant destination, which once was the city’s first official large-scale shopping mall. The companies have transitioned the expansive space from a retail center to an almost 500,000-square-foot bustling community hub ideal for playing, working, congregating and celebrating the arts. Is New 90 Day High Low • Jan 07
New 90-day high: €17.00 The company is up 19% from its price of €14.30 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.81 per share. Recent Insider Transactions • Dec 03
President & COO of Western Operations recently sold €236k worth of stock On the 2nd of December, Norman Hames sold around 15k shares on-market at roughly €15.71 per share. In the last 3 months, they made an even bigger sale worth €262k. Insiders have been net sellers, collectively disposing of €1.3m more than they bought in the last 12 months. Reported Earnings • Nov 11
Third quarter 2020 earnings released: EPS US$0.12 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2020 results: Revenue: US$292.0m (flat on 3Q 2019). Net income: US$6.16m (up 93% from 3Q 2019). Profit margin: 2.1% (up from 1.1% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Nov 11
Revenue beats expectations Revenue exceeded analyst estimates by 15%. Over the next year, revenue is forecast to grow 8.4%, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Is New 90 Day High Low • Nov 11
New 90-day high: €15.80 The company is up 5.0% from its price of €15.00 on 12 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €17.33 per share. Is New 90 Day High Low • Sep 25
New 90-day low: €11.90 The company is down 10.0% from its price of €13.20 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.15 per share. Recent Insider Transactions • Sep 23
President & COO of Western Operations recently sold €262k worth of stock On the 18th of September, Norman Hames sold around 20k shares on-market at roughly €13.09 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.0m more than they bought in the last 12 months. 
